Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News BioNxt Solutions Inc C.BNXT

Alternate Symbol(s):  BNXTF

Healthcare
BioNxt Solutions Inc. is a bioscience company. The Company is focused on drug formulations and delivery systems, diagnostic screening tests, and new active pharmaceutical ingredient investment opportunities, including precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization of emerging active... see more

Recent & Breaking News (CSE:BNXT)

BioNxt Reports Commercialization of ODF Cladribine Product for MS Next Steps

Accesswire March 18, 2024

BioNxt Reports Successful Results From ODF Cladribine PK Study

Accesswire March 13, 2024

BioNxt completes study on its oral MS treatment

Jonathon Brown March 4, 2024

BioNxt Reports Completion of ODF Cladribine PK Study

Accesswire March 4, 2024

BioNxt Solutions Finalizes Agreement

Accesswire February 16, 2024

BioNxt reveals results from multiple sclerosis treatment study

Jocelyn Aspa February 7, 2024

BioNxt Reports Successful Results From ODF Cladribine Toxicity Study

Accesswire February 7, 2024

BIONXT SOLUTIONS ANNOUNCES CLOSING OF FINAL TRANCHE OF NON-BROKERED PRIVATE PLACEMENT

Accesswire January 29, 2024

BioNxt Solutions Announces Completion of Cladribine ODF Toxicity Study and Financing

Accesswire December 21, 2023

BioNxt Receives Delivery of Premium Commercial Coating and Cutting Equipment for Commercial Manufacturing of Drug Delivery Products

Accesswire December 12, 2023

BioNxt Solutions Announces Completion of Debenture and Interest Settlement and Issuance of Finder's Warrants

Accesswire December 8, 2023

Bionxt Solutions Announces Convertible Debenture and Interest Settlement

Accesswire November 24, 2023

BioNxt Accelerates Cladribine ODF Clinical and Commercialization Strategy for Multiple Sclerosis Treament

Accesswire November 20, 2023

BioNxt Reports on New Cladrabine ODF Product Development and Commercialization Program

Accesswire November 15, 2023

BioNxt Signs Definitive Agreement For 100% Acquisition of IP And Co-Development of Cladribine ODF Drug Reformulation for The Treatment of Multiple Sclerosis

Accesswire November 13, 2023

BioNxt Solutions Reports on Barcelona CPHI Conference

Accesswire November 6, 2023

BioNxt Solutions Announces Closing of Third and Final Tranche of Non-Brokered Private Placement

Accesswire October 27, 2023

BioNxt Solutions Announces Change of Directors

Accesswire October 3, 2023

Bionxt Solutions Announces Closing of Second Tranche of Non-Brokered Private Placement

Accesswire September 28, 2023

BioNxt Solutions Announces Non-Brokered Private Placement

Accesswire August 4, 2023